Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15702064 | 0.90 | SSTR3 (0.52) | SSTR3HDAC8HDAC2HDAC3HDAC4 | |
| SCHEMBL15702069 | 0.89 | SSTR3 (0.51) | SSTR3HDAC8HDAC2HDAC3HDAC4 | |
| SCHEMBL18102693 | 0.87 | SSTR3 (0.51) | SSTR3HDAC8CTSLSIRT2SIRT1 | |
| SCHEMBL12836787 | 0.87 | SIRT5 (0.39) | HDAC8HDAC1CTSLSIRT2SIRT1 | |
| SCHEMBL16266210 | 0.85 | SSTR3 (0.44) | SSTR3CTSLPSMB1PSMB5PSMB2 | |
| SCHEMBL15702071 | 0.85 | SSTR3 (0.45) | SSTR3HDAC8HDAC2HDAC3HDAC4 | |
| SCHEMBL29649540 | 0.85 | FOLH1 (0.45) | SSTR3 | |
| SCHEMBL25361958 | 0.84 | SSTR3 (0.50) | SSTR3HDAC8CTSLSIRT2SIRT1 | |
| SCHEMBL25361946 | 0.84 | SSTR3 (0.50) | SSTR3HDAC8CTSLSIRT2SIRT1 | |
| SCHEMBL12435181 | 0.82 | FOLH1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545613-B9 | AURISTATIN CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS INC (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2357006-A2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | Seattle Genetics, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2353611-A2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | Seattle Genetics, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-1545613-B1 | AURISTATIN CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS INC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7851437-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851437-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7829531-B2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-7659241-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | SSTR3 1578/4885HDAC8 2257/4885HDAC2 2853/4885 |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | SSTR3 1578/4885HDAC8 2257/4885HDAC2 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.